Tradestie Institutional Equity Comparison Engine

ACAD vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACAD trades at 15.8x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
ACAD 15.8x vs CDT N/M Fwd P/E
Growth & Margin Winner ACAD
Op Margin 10.2% vs 0.0% ยท YoY +22.8% vs +0.0%
Momentum & Technical Winner ACAD
1Y -25.9% vs -86.8% ยท 52W Pos 8% vs 2%
Options & Structure Winner ACAD
BREAKDOWN (6th %ile IV) vs BREAKDOWN (N/A IV)
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
1M Return -15.76%
1Y Return -25.93%
Forward P/E 15.8x
Unified AI Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACAD -25.93% CDT -86.78% Spread: +60.85 pp (ACAD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACAD TTM Op. Margin: 10.2% CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACAD vs CDT. Trailing 12-month operating profitability (ACAD 10.2% vs CDT 0.0%) and valuation multiples (ACAD 15.8x vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACAD (10) vs CDT (0)
Institutional Metric ACAD CDT Criterion Row Winner
Market Capitalization Scale $3.0B $507,528 Larger Scale ACAD
Trailing P/E Ratio Valuation 8.3x N/M Lower Multiple ACAD
Forward P/E Ratio Valuation 15.8x N/M Lower Multiple ACAD
Revenue Growth (YoY) Growth +22.8% +0.0% Higher Growth ACAD
Operating Margin (TTM) Profitability 10.2% 0.0% Higher Margin ACAD
Net Profit Margin Profitability 30.1% 0.0% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency 31.4% -69.7% Higher ROE ACAD
52-Week Range Position Momentum 8% ($16โ€“$31) 2% ($0โ€“$11) Stronger Trend ACAD
Beta / 30D Volatility Risk Regime 0.15ฮฒ ยท 90% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk ACAD
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite ACAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACAD vs CDT Buy Guide
ACAD BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACAD nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.